Pharmacokinetics of pentoxifylline and its metabolites in healthy mice and in mice infected with Candida albicans

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 9, 1998, Pages 2405-2409

  Miller, Kenneth ^a,f   Louie, Arnold ^b   Baltch, Aldona L ^b,e   Smith, Raymond P ^b   Davis, Patrick J ^d   Gordon, Morris A ^c  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c WADSWORTH CENTER   (United States)

^d UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^e STRATTON VA MEDICAL CENTER   (United States)

^f AMERICAN ASSOCIATION OF COLLEGES OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; PENTOXIFYLLINE;

ANIMAL MODEL; ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0031662749     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.9.2405     Document Type: Article

References (13)

1. Beermann, B., R. Ings, J. Mansby, J. Chamberlain, and A. McDonald. 1985. Kinetics of intravenous and oral pentoxifylline in healthy subjects. Clin. Pharmacol. Ther. 37:25-28.
2. Burrows, J. L. 1987. Determination of oxpentifylline and three metabolites in plasma by automated capillary gas chromatography using nitrogen-selective detection. J. Chromatogr. 423:139-146.
3. Honess, D. J., I. F. Dennis, and N. M. Bleehen. 1993. Pentoxifylline: its pharmacokinetics and ability to improve tumor perfusion and radiosensitivity in mice. Radiother. Oncol. 28:208-218.
4. Lechner, A. J., L. R. Rouben, L. H. Potthoff, T. L. Tredway, and G. M. Matuschak. 1993. Effects of pentoxifylline on tumor necrosis factor production and survival during lethal E. coli sepsis vs. disseminated candidiasis with fungal septic shock. Circ. Shock 39:306-315.
5. Louie, A., A. L. Baltch, M. A. Franke, W. J. Ritz, R. P. Smith, J. K. Singh, and M. A. Gordon. 1996. Effect of pentoxifylline on the course of systemic Candida albicans infection in mice. J. Antimicrob. Chemother. 37:943-954.
6. Noel, P., S. Nelson, R. Bokulic, G. Bagby, H. Lippton, G. Lipscomb, et al. 1990. Pentoxifylline inhibits lipopolysaccharide-induced serum tumor necrosis factor and mortality. Life Sci. 47:1023-1029.
7. Opal, S. M., A. S. Cross, N. M. Kelly, G. C. Sadoff, M. W. Bodmer, and J. E. Palardy. 1990. Efficacy of a monoclonal antibody directed against tumor necrosis factor in protecting neutropenic rats from lethal infection with Pseudomonas aeruginosa. J. Infect. Dis. 161:1148-1152.
8. Raju, P. I., K. C. Tolman, P. J. Davis, T. M. Ludden, T. K. Roy, and F. E. Johnson. 1993. Distribution and metabolism of pentoxifylline in non-tumor-bearing mice. J. Med. (Westbury) 24:353-368.
9. Rowland, M., and T. N. Tozer (ed.). 1989. Clinical pharmacokinetics, p. 12-13. Lea and Febiger, Philadelphia, Pa.
10. Sáez-Llorens, X., O. Ramilo, M. M. Mustafa, J. Mertsola, C. de Alba, E. Hansen, and G. H. McCracken, Jr. 1990. Pentoxifylline modulates meningeal inflammation in experimental bacterial meningitis. Antimicrob. Agents Chemother. 34:837-843.
11. Smith, R. V., E. S. Waller, J. T. Doluisio, M. T. Bauza, K. P. Surendra, I. Ho, and H. B. Lassman. 1986. Pharmacokinetics of orally administered pentoxifylline in humans. J. Pharm. Sci. 75:47-52.
12. Strieter, R. M., D. G. Remick, P. A. Ward, R. N. Spengler, J. P. Lynch III, J. Larrick, and S. L. Kunkel. 1988. Cellular and molecular regulation of tumour necrosis factor-alpha production by pentoxifylline. Biochem. Biophys. Res. Commun. 155:1230-1260.
13. Sullivan, G. W., H. T. Carper, W. J. Novick, Jr., and G. L. Mandell. 1988. Inhibition of the inflammatory action of interleukin-1 and tumor necrosis factor (alpha) on neutrophil function by pentoxifylline. Infect. Immun. 56: 1722-1729.